MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.19
-0.58
-4.54%
After Hours: 12.19 0 0.00% 16:00 01/24 EST
OPEN
12.78
PREV CLOSE
12.77
HIGH
13.18
LOW
12.12
VOLUME
557.98K
TURNOVER
--
52 WEEK HIGH
28.79
52 WEEK LOW
7.76
MARKET CAP
451.92M
P/E (TTM)
-7.4969
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VYGR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VYGR News

  • Can You Imagine How Voyager Therapeutics's (NASDAQ:VYGR) Shareholders Feel About The 52% Share Price Increase?
  • Simply Wall St..01/10 15:25
  • Atlas, MPM, Partners funnel $49M into a new gene-silencing startup
  • American City Business Journals.12/17/2019 11:00
  • Is Voyager Therapeutics, Inc. (VYGR) Going To Burn These Hedge Funds ?
  • Insider Monkey.12/11/2019 15:32
  • Voyager Therapeutics Enters Sales Agreement With Cowen For $100M Common Stock
  • Benzinga.12/03/2019 21:20

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
More

Webull offers Voyager Therapeutics Inc (VYGR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.